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COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS
PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN
CHINA
Staginnus U1, Russell S2
1Premor Associates, New York, NY, USA; 2Premor Associates, Madrid,
Spain
OBJECTIVE: Viral transmission of current (e.g., HIV) infectious
blood-borne pathogens via platelet transfusion is high in China,
and emerging pathogens (e.g., SARS) continue to threaten the
blood supply despite recent advances in blood-banking proce-
dures and security. The INTERCEPT Blood System (IBS) for
platelets has been developed to further reduce pathogen trans-
mission risks during platelet transfusions. The objective of this
study was to assess the cost-effectiveness of using random-donor
platelets (RDP) processed with IBS in China. METHODS: A 
literature-based decision analysis model was used to assess the
cost-effectiveness of the IBS in four patient populations that
account for most of the platelet usage in China: 1) a ten-year old
male with acute lymphocytic leukaemia (ALL); 2) a 50-year old
male with non-Hodgkin’s lymphoma (NHL); 3) a 60-year 
old male undergoing heart bypass surgery (CABG); and 4) a 
70-year old female undergoing a hip arthroplasty. Pathogen
exposure included HIV, HCV, HBV and bacterial contamination.
The model compared projected quality-adjusted life-year saved
(QALY) and costs for patients receiving untreated vs. treated
platelets. RESULTS: The incremental cost per QALY gained by
using RDP + IBS vs. RDP ranged in the most conservative sce-
nario from Yuan321,000–Yuan4,665,000. Sensitivity analysis
including transmission rates reported from epidemic regions
improved the cost-effectiveness dramatically ranging from
Yuan38,000–Yuan565,000. The model was most sensitive to the
rate of HIV transmission and the mortality from bacterial infec-
tion. CONCLUSION: IBS for platelets would be a cost-effective
measure to improve blood safety in China. Given the relatively
high risk of HIV and other viral agents in China as compared to
developed countries, and the recent history of emerging and
migrating viruses, pathogen inactivation with IBS may be con-
sidered as a desirable strategy to signiﬁcantly improve the safety
of platelet transfusions.
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Magnetti S, Oinonen M, Matuszewski K
University HealthSystem Consortium, Oak Brook, IL, USA
OBJECTIVES: To describe patient characteristics and selected
outcomes related to the inpatient use of recombinant human
factor VII (RHF7) in US academic health centers (AHC).
METHODS: All discharges from the fourth quarter 2001 to
third quarter 2004 were captured from AHCs participating in
the University HealthSystem Consortium’s Clinical Database-
Pharmacy. Descriptive statistics were used to evaluate patient
demographics and coded diagnoses. Other outcomes of interest
included in-hospital mortality, total hospital costs and charges,
and length of stay. RESULTS: A total of 37 AHCs were included
in the analysis, representing 1889 discharges. The mean patient
age was 43 years (SD 23, median 47). Sixty-six percent were
male and 51% were white. Ten DRGs accounted for approxi-
mately 50% of the cases, with the top 3 most frequently cited
being those for tracheostomy (11%), coagulation disorders
(9%), and liver transplant (8%). Of the total 645 unique primary
diagnoses, 13% were related to chronic liver diseases or seque-
lae followed by coagulation factor deﬁciency and defects as the
next most frequently cited reasons for admission (9%). The
mean length of stay was 23 days (SD 30, median 13). The mean
total hospital cost per case was $121,240 (SD $151,047, median
$72,351). The mean total hospital charges per case were
$281,548 (SD $382,151, median $156,048). The in-hospital
mortality rate was 39%. CONCLUSION: RHF7F carries FDA-
approval for marketing (in 1999) in bleeding patients with hemo-
philia A or B who have developed antibody inhibitors to factor
VIII or IX. Given the wide range of DRGs and primary diag-
noses recorded, substantial off-label use appears to be common
medical practice.
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A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS:
ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN
SELECTED CHRONIC DISEASES
Wang PF, Saunders WB, Gaylord B,Vardireddy N
Premier Health Informatics, Charlotte, NC, USA
OBJECTIVES: 1) To understand the prevalence of anemia
among hospital inpatients with selected chronic diseases; and 2)
to evaluate current anemia treatment strategy in acute care hos-
pitals. METHODS: Using Premier’s PerspectiveTM Comparative
database, the largest US hospital database, all inpatients dis-
charged between January, 2003 and December, 2003 with a
primary diagnosis of chronic kidney disease, congestive heart
failure, diabetes, cancer, AIDS, and rheumatoid arthritis were
retrieved. Anemia was identiﬁed using ICD codes (280–285).
Patient demographics, insurance type, institution characteristics,
severity, and anemic treatment patterns were examined. Out-
comes variables included length of stay, total cost, and in-
hospital mortality. RESULTS: Of 300,494 subjects, close to a
quarter (23.5%) were diagnosed with anemia. Prevalence rates
varied by disease from 46.1% (chronic renal insufﬁciency) to
20.2% (diabetes). Only 20.4% anemics received epoetin alfa and
13.7% received iron supplement. Anemic patients were associ-
ated with longer length of stay (4.9 vs. 7.6 days, P < 0.01), higher
total hospitalization cost ($8014 vs. $11,752, P < 0.01) and ele-
vated in-hospital mortality (4.3% vs. 6.1%). CONCLUSIONS:
Anemia is associated with many chronic diseases among acute
care inpatient populations. It is often under-treated with less than
one third of the anemic patients receiving readily available drugs.
When left untreated anemia can be associated with suboptimal
clinical and economic outcomes.
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COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE
ADHERENCE: WHAT IS THE QUALITY OF THE EVIDENCE?
Elliott RA1, Barber N2, Horne R3
1Harvard University, Boston, MA, USA; 2University of London,
London, UK; 3University of Brighton, Brighton, Sussex, UK
OBJECTIVE: To determine whether cost effectiveness evidence
on adherence-enhancing interventions (AEIs) was of sufﬁcient
quality to inform policy decision-making. METHODS: A com-
puterised search of Embase, Medline, Cinahl, Econlit, NHSEED,
Psychlit, ePIC and Cochrane databases from January, 1980 to
April, 2004 was performed. English-language human subject
articles were identiﬁed using an inclusive search strategy. Studies
that appeared to assess the cost effectiveness of medication
adherence-enhancing interventions were included. Methodologic
rigor was assessed using 15 clinical, economic and adherence-
